TY - JOUR T1 - XELIRI or FOLFIRI as Salvage Therapy in Advanced Pancreatic Cancer JF - Anticancer Research JO - Anticancer Res SP - 4785 LP - 4790 VL - 30 IS - 11 AU - STEFANO CEREDA AU - MICHELE RENI AU - ALESSIA ROGNONE AU - MICHELE GHIDINI AU - CARMEN BELLI AU - SIMONA LONGONI AU - CLARA FUGAZZA AU - MATTEO BRIOSCHI AU - ROBERTO NICOLETTI AU - GIANPAOLO BALZANO AU - PAOLO PASSONI AU - EUGENIO VILLA Y1 - 2010/11/01 UR - http://ar.iiarjournals.org/content/30/11/4785.abstract N2 - Background: More than half of patients with pancreatic adenocarcinoma (PA) are candidates for further treatment when they experience upfront treatment failure. Patients and Methods: Patients with gemcitabine-resistant PA, age <76 years and Karnofski performance status (KPS) >50 were treated with a XELIRI or FOLFIRI regimen until progressive disease or a maximum of six months. As this was an observational study, no statistical design was performed. Results: Between July 2007 and December 2009, 34 patients (median age 60 years; median KPS 90) were treated with XELIRI (26) or FOLFIRI (8) regimen. Grade >2 toxicity consisted of neutropenia in 9% of patients, anemia and fatigue in 3% and hand-foot syndrome in 12%. Median progression-free survival was two months (range 1-4). Maximum response was stable disease in four patients (12%). Median survival was 4.2 (range 1-15) months. Conclusion: Fluoropyrimidine and irinotecan combination does not seem to have any role in the treatment of gemcitabine-resistant PA. ER -